Personal CGM
Several personal CGM systems are available in the United States for daily use by people with diabetes. The Abbott FreeStyle Libre flash CGM system received FDA approval in September 2017 for stand-alone use (i.e., not requiring use of an insulin pump) with intermittent scanning. The system consists of the FreeStyle Libre sensor, which is wearable for up to 10 days, and the FreeStyle Libre reader. The system measures glucose levels every minute and records readings every 15 minutes. The user holds the reader over the sensor to scan the current glucose level to the reader. Both a glucose level and a trend arrow indicating direction and rate of change are displayed with each scan of the sensor. This system has a MARD of 9.7%. The sensor comes factory-calibrated, requiring no calibration by the user, and displays the most recent 8 hours of glucose data for patient review with each scan. Data history of up to 90 days can be uploaded from the reader to the FreeStyle LibreView software for evaluation by the user at home or by the health care provider with the patient during a clinic visit.
The Medtronic Enlite sensor is used with Medtronic MiniMed 530G and 630G insulin pumps. Real-time glucose data and rate-of-change trend arrows are available every 5 minutes on the pump screen, and both pumps use Medtronic SmartGuard technology, which will suspend insulin delivery for up to 2 hours when glucose levels fall below a preset threshold. The Enlite sensor requires calibration every 12 hours. The newer Guardian Sensor 3 glucose sensor and the Guardian Link transmitter are used with the Medtronic MiniMed 670G insulin pump system. Approved by the FDA in September 2016, the 670G is the first hybrid closed-loop insulin pump-CGM system to become available in the United States. The Guardian Sensor 3 may be worn for up to 7 days and is Medtronic's most accurate glucose sensor, with a MARD of 9.6% with abdominal insertion and 8.7% with arm insertion, based on three to four calibrations per day. The three Medtronic MiniMed pumps can all be downloaded to the Medtronic CareLink website for CGM data review.
Stand-alone real-time CGM systems approved for use in the United States include the Dexcom G4 Platinum, Dexcom G5 Mobile, and Dexcom G6 systems (Dexcom, San Diego, CA). The G4 Platinum and G5 Mobile systems feature the Dexcom Platinum G4/G5 sensor, which is placed by the user and can be worn for up to 7 days. Users must calibrate these systems twice daily with fingerstick blood glucose measurements. The G4 Platinum transmitter uses radio wave technology, and glucose data and trend arrows may be viewed continuously on a Dexcom G4 receiver, as well as on the Glucose is rapidly rising (>3 mg/dL per minute) Glucose is rising (2-3 mg/dL per minute) Glucose is slowly rising (1-2 mg/dL per minute) Glucose is steady (not increasing or decreasing >1 mg/dL per minute) Glucose is slowly falling (1-2 mg/dL per minute) Glucose is falling (2-3 mg/dL per minute) Glucose is rapidly falling (>3 mg/dL per minute) may be viewed on the Dexcom G5 receiver, the Tandem t:slim X2 insulin pump, the Dexcom G5 Mobile App on most Apple and Android devices. The G4/G5 sensor has a MARD of 9.0% when used with devices that include the most current Dexcom software (4). The Dexcom G6 CGM system received FDA approval in March 2018. This newest sensor and transmitter system will require no calibrations or fingerstick blood glucose confirmations to make diabetes treatment decisions. The sensor may be worn for up to 10 days. A previous issue with acetaminophen interference has been resolved, and the overall MARD is 9.0% (5). 
